

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A method for treating skin disorder in a patient in need thereof, the method comprising the step of administering a therapeutically effective amount of a liquid solution comprising a botulinum toxin to a location of a skin disorder of the patient, wherein the administration of the botulinum toxin reduces at least one symptom of the skin disorder, thereby treating the skin disorder;

wherein the solution is administered by intradermal injection or subdermal injection with a needle per session;

wherein the skin disorder comprises a wart, a callus, a swelling or scarring of a nerve that connects two toes, or a bunion; and,

wherein the botulinum toxin administered is less than the amount used to paralyze a muscle.

2. (Previously Presented) The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A, a botulinum toxin type B, a botulinum toxin type C1, a botulinum toxin type D, a botulinum toxin type E, a botulinum toxin type F, or a botulinum toxin type G.

3. (Original) The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.

4. (Original) The method of claim 1, wherein the botulinum toxin is administered in an amount of between about 1 unit and about 3,000 units.

5. (Previously Presented) The method of claim 1, wherein the subdermal injection is a subcutaneous injection or an intramuscular injection.
6. (Previously Presented) The method of claim 1, wherein the wart is a common wart, a plantar wart or a flat wart.
7. (Canceled)
8. (Previously Presented) The method of claim 1, wherein the skin disorder is treated by reducing a pain associated with the skin disorder.
9. (Previously Presented) The method of claim 1, wherein the skin disorder is treated by reducing inflammation associated with the skin disorder.
10. (Previously Presented) The method of claim 1, wherein the skin disorder is treated by reducing the size of the skin disorder.
11. (Canceled)
12. (Currently Amended) A method for treating skin disorder in a patient in need thereof, the method comprising a step of administering a therapeutically effective amount of a liquid solution comprising a botulinum toxin to a location of a skin disorder of the patient, wherein the administration of the botulinum toxin reduces at least one symptom of the skin disorder, thereby treating the skin disorder.

wherein the solution is administered by intradermal injection or subdermal injection with a needle per session;

wherein the skin disorder comprises a dermatofibroma, a mole, a granuloma, or a keratose; and,

wherein the botulinum toxin administered is less than the amount used to paralyze a muscle.

13. (Previously Presented) The method of claim 12, wherein the botulinum toxin is a botulinum toxin type A, a botulinum toxin type B, a botulinum toxin type C1, a botulinum toxin type D, a botulinum toxin type E, a botulinum toxin type F, or a botulinum toxin type G.
14. (Previously Presented) The method of claim 12, wherein the botulinum toxin is a botulinum toxin type A.
15. (Previously Presented) The method of claim 12, wherein the botulinum toxin is administered in an amount of between about 1 unit and about 3,000 units.
16. (Previously Presented) The method of claim 12, wherein the skin disorder is treated by reducing a pain associated with the skin disorder.
17. (Previously Presented) The method of claim 1, wherein the callus is a corn.
18. (Previously Presented) The method of claim 17, wherein the corn develops due to a hammertoe.
19. (Previously Presented) The method of claim 12, wherein the subdermal injection is a subcutaneous injection or an intramuscular injection.
20. (Previously Presented) The method of claim 12, wherein the skin disorder is treated by reducing inflammation associated with the skin disorder.
21. (Previously Presented) The method of claim 12, wherein the skin disorder is treated by reducing the size of the skin disorder.
22. (Previously Presented) The method of claim 12, wherein the mole is a typical mole or a dysplastic mole.
23. (Previously Presented) The method of claim 12, wherein the granulation is a pyogenic granuloma.

24. (Previously Presented) The method of claim 12, wherein the keratose is a seborrheic keratose.

25-27. (Canceled)